Patents by Inventor Arjune Premsukh

Arjune Premsukh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-EPCAM antibodies and methods of use
    Patent number: 9822182
    Abstract: The present disclosure is related to compositions of antibodies and immunoconjugates that potentially lack T-cell epitopes and elicit reduced immune response. The antibody may be an antibody fragment, such as Fab, Fab?, F(ab?)2, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, bispecific antibody fragments, multimers, and any combination thereof. In a further embodiment, the antibody may bind to an antigen epithelial cell adhesion molecule (EpCAM). In another embodiment, an immunoconjugate may comprise an antibody attached to an effector molecule, wherein the effector molecule may be a radioisotope, an antineoplastic agent, an immunomodulator, a biological response modifier, lectin, a toxin, a chromophore, a fluorophore, a chemiluminescent compound, an enzyme, a metal ion, and any combination thereof.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: November 21, 2017
    Assignee: VIVENTIA BIO INC.
    Inventors: Jeannick Cizeau, Arjune Premsukh, Shilpa Chooniedass, Glen MacDonald, Joycelyn Entwistle
  • ANTI-EPCAM ANTIBODIES AND METHODS OF USE
    Publication number: 20160237164
    Abstract: The present disclosure is related to compositions of antibodies and immunoconjugates that potentially lack T-cell epitopes and elicit reduced immune response. The antibody may be an antibody fragment, such as Fab, Fab?, F(ab?)2, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, bispecific antibody fragments, multimers, and any combination thereof. In a further embodiment, the antibody may bind to an antigen epithelial cell adhesion molecule (EpCAM). In another embodiment, an immunoconjugate may comprise an antibody attached to an effector molecule, wherein the effector molecule may be a radioisotope, an antineoplastic agent, an immunomodulator, a biological response modifier, lectin, a toxin, a chromophore, a fluorophore, a chemiluminescent compound, an enzyme, a metal ion, and any combination thereof.
    Type: Application
    Filed: October 2, 2014
    Publication date: August 18, 2016
    Inventors: Jeannick CIZEAU, Arjune PREMSUKH, Shilpa CHOONIEDASS, Glen MACDONALD, Joycelyn ENTWISTLE
  • Optimized nucleic acid sequences for the expression of VB4-845
    Patent number: 8318472
    Abstract: An optimized nucleic acid sequence encoding the immunoconjugate VB4-845 is disclosed. Modifications to the original VB4-845 nucleic acid sequence include optimization of the sequences encoding the VH region, VL region, linkers and pseudomonas exotoxin A. The modifications improved the yield of VB4-845 in an Escherichia coli expression system.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: November 27, 2012
    Assignee: Viventia Biotechnologies Inc.
    Inventors: Jeannick Cizeau, Glen MacDonald, Arjune Premsukh
  • Optimized Nucleic Acid Sequences For The Expression of VB4-845
    Publication number: 20100267086
    Abstract: An optimized nucleic acid sequence encoding the immunoconjugate VB4-845 is disclosed. Modifications to the original VB4-845 nucleic acid sequence include optimization of the sequences encoding the VH region, VL region, linkers and pseudomonas exotoxin A.
    Type: Application
    Filed: September 26, 2008
    Publication date: October 21, 2010
    Inventors: Jeannick Cizeau, Glen MacDonald, Arjune Premsukh